ATTAINMENT OF CLINICAL REMISSION IN RHEUMATOID ARTHRITIS: COMPREHENSIVE ANALYSIS OF CONTRIBUTING FACTORS

Background: Rheumatoid arthritis (RA) poses a persistent challenge marked by chronic joint inflammation and progressive damage. The pinnacle of therapeutic success in RA lies in achieving clinical remission, indicative of both symptom alleviation and profound inflammatory quiescence. Objectives: The paramount therapeutic objective in managing rheumatoid arthritis (RA) is the attainment of clinical remission, characterized by a profound absence of inflammatory signs and symptoms. This study aimed to meticulously evaluate the prevalence of remission in RA patients and rigorously identify potential predictive factors influencing this clinically significant outcome. Methods: Employing a meticulously structured cross-sectional and descriptive methodology, this investigation encompassed the entire spectrum of adult patients diagnosed with RA, strictly adhering to the rigorous ACR/EULAR 2010 criteria. The study was conducted at the Rheumatology Department of HMIMV-Rabat over a meticulously monitored 12-month period. Clinical remission was meticulously defined as the achievement of a Disease Activity Score (DAS28) less than 2.6, with an exhaustive analysis of potential predictive factors influencing remission. Results: A meticulous inclusion of 194 patients divulged a significant preponderance of females (80.92%), with an average age of 56.60 ± 10.8 years. A detailed exploration of their medical history revealed an average disease duration of 8.4 ± 7.29 years. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected in 62.9% and 66.5% of patients, respectively. The calculated mean DAS28 CRP was 4.48. Erosive manifestations of RA were identified in 71.1% of patients. Background treatments comprised methotrexate in 91.8%, sulfasalazine in 45.3%, leflunomide in 27.9%, and synthetic disease-modifying antirheumatic drugs in 12.6%. Corticosteroids were prescribed in 90.7% of patients. A meticulous examination of the data revealed remission in 35% of patients. Multivariate analysis further elucidated that both conventional background treatments and biologics were significantly associated with achieving remission. Conclusion: Within this meticulously scrutinized cohort, the attainment of remission in RA at the one-year follow-up was discerned in 35% of patients. These compelling findings underscore the pivotal role of therapeutic interventions, specifically the administration of conventional background treatments and biologics, in effectively steering patients toward the coveted state of clinical remission in the management of rheumatoid arthritis. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2024-eular.6124 Keywords: Clinical Trial, Descriptive Studies Citation: , volume 83, supplement 1, year 2024, page 1232Session: Autoinflammatory diseases, Vexas and other monogenic diseases (Publication Only)

Clinical Trial, Descriptive Studies